Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy

After three months, OPGx-BEST1 was well tolerated with no reports of observed ocular inflammation or adverse events.
Nasdaq

Opus Genetics Reports Positive Phase 3 Results for Phentolamine Ophthalmic Solution in Treating Night Driving Impairment in Keratorefractive Patients

Opus Genetics, Inc. announced positive results from its Phase 3 clinical trial, LYNX-2, which evaluated Phentolamine Ophthalmic Solution 0.75% for treating chronic night driving impairment in ...
The Manila Times

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...
Seeking Alpha

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related ...
Seeking Alpha

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating ...
Nasdaq

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 2025; initial data from all three patients anticipated in Q3 2025 FDA Type D meeting ...